allergan

Allergan acquires neurotoxin specialist Bonti in $195m deal

pharmafile | September 17, 2018 | News story | Sales and Marketing Allergan, Bonti, Botox, Neurotoxin, acquisition, deal 

The Dublin-headquartered multinational Allergan have agreed to acquire the clinical stage biotech Bonti in a deal worth more than $195 million. The deal will see Botox drugmaker Allergan acquire Bonti’s portfolio of neurotoxins.

In particular, following the completion of the acquisition Allergan will obtain the global rights to the experimental EB-001A and AB-001T programmes being developed for both therapeutic and aesthetic use.

The deal, which involves an upfront payment of $195 million and additional payments in connection with future commercial milestones, will act to expand Allergan’s portfolio of injectable facial treatments.

“We’re excited about the development and commercial prospects for our novel programs within Allergan’s leading Medical Aesthetics portfolio,” commented Fauad Hasan, CEO and co-founder at Bonti. “The promise of benefitting more consumers worldwide with our novel neurotoxin programs plus Allergan’s stature and resources in this market will help realize our team’s and investors’ aims. We could not envision a more compelling acquirer or better strategic fit”

In the US alone there is huge potential for faster acting shorter-duration facial injectable treatments with an estimated 65 million customers considering such cosmetic procedures.

“The acquisition of Bonti is a strategic investment for the future of our Medical Aesthetics business and has the potential to enhance our best-in-class Medical Aesthetics pipeline,” said Brent Saunders, Chairman and CEO of Allergan. “With the Medical Aesthetics market vastly expanding, a fast-acting neurotoxin with a 2 to 4-week duration will be an attractive option for consumers, particularly those who are considering a Medical Aesthetics treatment for the first time.”

Louis Goss

Related Content

Vertex to acquire Alpine Immune Sciences for $4.9bn

Vertex Pharmaceuticals and Alpine Immune Sciences have announced that they have entered into a definitive …

Johnson & Johnson to acquire Shockwave Medical

Johnson & Johnson (J&J) and Shockwave Medical have announced that they have entered into a …

AbbVie to acquire Landos Biopharma for approximately $137.5m

AbbVie and Landos Biopharma have announced that they have entered into a definitive agreement under …

Latest content